Dublin, December 31, 2021 (GLOBE NEWSWIRE) – The “Chinese Docetaxel Market Investigation Report 2021-2025” the report was added to ResearchAndMarkets.com offer.
According to the market research, the sales value of Docetaxel in the Chinese market has remained constant from 2016 to 2019. Due to the impact of the COVID-19 outbreak on all diagnostic and treatment services Chinese hospitals, the value of Docetaxel sales in the Chinese market declined to CNY 1.112 billion in 2020, down 16.79% year-on-year. The sales value CAGR of Docetaxel in the Chinese market from 2016 to 2020 was -3.86%.
Docetaxel, marketed under the brand name Taxotere, is an anti-tumor drug paclitaxel used for the treatment of locally advanced or metastatic non-small cell lung cancer. Docetaxel injection was first developed and produced by the French company Rhône Planck Lean (later renamed Aventis, also known as Sanofi-Aventis). Its marketing was first approved by the European Union in 1995 and approved in China in 1996. By 2020, there were several manufacturers in the Chinese market for docetaxel.
The analyst expects that with the mitigation of the COVID-19 outbreak, Docetaxel sales will experience restorative growth from 2021 to 2025. In addition, 4.57 million new cancer cases have been reported. diagnosed in China in 2020, and the overall cancer incidence has increased by about 3.9% per year.
Therefore, the volume of sales of docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer will increase with the increase in the number of colon cancer patients and it is possible that sales will increase. At the same time, compared to similar drugs, Docetaxel is safer and more effective, the sales volume will increase in the future.
The impact of COVID-19 on the Chinese docetaxel market
2016-2020 Chinese docetaxel sales value
Competitive landscape of the Chinese docetaxel market
Price of docetaxel in China
Docetaxel Price in China by Regions and Manufacturers
Analysis of factors affecting the development of the Chinese docetaxel market
Prospects for the Chinese docetaxel market from 2021 to 2025
Main topics covered:
1 Relevant concepts of docetaxel
1.1 Indications for docetaxel
1.2 Development of Docetaxel in China
1.3 Government approval of docetaxel in China
1.4 The impact of COVID-19 on sales of docetaxel in China
2 Sales of Docetaxel in China, 2016-2020
2.1 Sale value of docetaxel
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Docetaxel sales volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 China Sales of Docetaxel by Dosage Form, 2016-2020
2.3.2 Analysis of another dosage form
3 Analysis of Major Manufacturers of Docetaxel in China in 2020
3.1 Major Manufacturers of Docetaxel Market Share Analysis
3.1.1 Market Share by Sales Value Survey
3.1.2 Market Share by Sales Volume Survey
3.2 Aventis Pharma SA
3.2.1 Company profile
3.2.2 Sales of TAXOTERE (Docetaxel of Aventis Pharma SA) in China
3.3 Jiangsu Hengrui Medicine Co., Ltd.
3.3.1 Company profile
3.3.2 Sales of Aisu (Docetaxel of Jiangsu Hengrui Medicine Co., Ltd.) in China
3.4 Shenzhen Wanle Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales of Xichun (Shenzhen Wanle Pharmaceutical Co., Ltd.) Docetaxel in China
3.5 Sichuan Huiyu Pharmaceutical Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Huiyu (Docetaxel of Sichuan Huiyu Pharmaceutical Co., Ltd.) in China
3.6 Yangtze River Pharmaceutical Group Co., Ltd.
3.6.1 Company Profile
3.6.2 Sales of Tianlun (Docetaxel of Yangtze River Pharmaceutical Group Co., Ltd.) in China
4 Docetaxel price for different manufacturers in China, 2020-2021
4.1 Aventis Pharma SA (TAXOTERE)
4.2 Jiangsu Hengrui Medicine Co., Ltd. (Aisu)
4.3 Shenzhen Wanle Pharmaceutical Co., Ltd. (Xichun)
4.4 Sichuan Huiyu Pharmaceutical Co., Ltd. (Huiyu)
4.5 Yangtze River Pharmaceutical Group Co., Ltd. (Tianlun)
5 China Docetaxel Market Outlook, 2021-2025
5.1 Factors influencing the development of the Chinese docetaxel market
5.1.1 The impact of COVID-19 on the Chinese docetaxel market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
Aventis Pharma SA
Jiangsu Hengrui Medicine Co. Ltd.
Shenzhen Wanle Pharmaceutical Co. Ltd.
Sichuan Huiyu Pharmaceutical Co. Ltd.
Yangtze River Pharmaceutical Group Co. Ltd.
For more information on this report, visit https://www.researchandmarkets.com/r/55fhaa
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900